Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Clinical research trials and Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer. Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "P" Clinical Trials Conditions > Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer



Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

For Condition: Ovarian Neoplasms
Status: No longer recruiting
Sponsor(s): Telik ,
Synopsis: The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - Histologic diagnosis of ovarian cancer - Recurrent or persistent disease following primary therapy - Measurable disease - Prior treatment with at least one but no more than three prior chemotherapy regimens - Resistant or refractory to platinum-based chemotherapy - At least 18 years of age - Good performance status (ECOG 0 to 1) - Adequate liver, renal and bone marrow function Exclusion criteria - Pregnant or currently breast feeding - Treatment with chemotherapy or immunotherapy within four weeks - Prior radiation to the whole pelvis
Total Enrollment: 40

Location and Contact Information:

Memorial Sloan-Kettering Cancer Center
New York City,  New York,  10021
United States
 

USC/Norris Comprehensive Cancer Center
Los Angeles,  California,  90033
United States
 

M.D. Anderson Cancer Center
Houston,  Texas,  77030
United States
 


Additional Information:
Study ID Numbers:  TLK286.2003; 
Study Start Date: 
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038428

Other Ovarian Neoplasms Studies:
1. Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

2. Removal of the ovaries/fallopian tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

3. Outcomes of Education and Counseling for BRCA1 Testing

4. Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

5. Pilot Study of ZD1839 (Iressa, Gefitinib) in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, or Cervical Cancer

Related Studies:

Other Ovarian Neoplasms Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
Modify your Search

  Other Ovarian Neoplasms Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103